G1 Therapeutics (GTHX) to Release Earnings on Wednesday

G1 Therapeutics (NASDAQ:GTHX - Get Free Report) will post its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect G1 Therapeutics to post earnings of ($0.19) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

G1 Therapeutics (NASDAQ:GTHX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.06. G1 Therapeutics had a negative return on equity of 106.04% and a negative net margin of 58.13%. The business had revenue of $14.87 million for the quarter, compared to the consensus estimate of $12.83 million. During the same quarter in the prior year, the business earned ($0.73) earnings per share. On average, analysts expect G1 Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

G1 Therapeutics Stock Performance

NASDAQ:GTHX traded down $0.20 during trading hours on Wednesday, reaching $3.99. The stock had a trading volume of 343,795 shares, compared to its average volume of 1,300,499. G1 Therapeutics has a 12-month low of $1.08 and a 12-month high of $5.00. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.45 and a current ratio of 3.87. The stock has a 50 day simple moving average of $3.66 and a 200 day simple moving average of $2.95. The stock has a market cap of $208.40 million, a P/E ratio of -4.20 and a beta of 1.73.

Insiders Place Their Bets

In related news, insider Rajesh Malik sold 28,600 shares of the firm's stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $4.62, for a total value of $132,132.00. Following the sale, the insider now directly owns 169,938 shares of the company's stock, valued at $785,113.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 8.23% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on GTHX. Needham & Company LLC restated a "buy" rating and issued a $12.00 price objective on shares of G1 Therapeutics in a research note on Friday, April 12th. Wedbush reaffirmed an "outperform" rating and issued a $5.00 price target (up from $4.00) on shares of G1 Therapeutics in a report on Wednesday, February 28th.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.